Journey Medical (DERM) Investor presentation summary

Market position and financial highlights

• Commercial-stage pharmaceutical company focused on proprietary and patented dermatology products, targeting a $5.8 billion market in acne, rosacea, and hyperhidrosis.

• 2025 net product revenues reached $61 million with adjusted EBITDA of $2.9 million.

• Solid balance sheet with $24.1 million in cash as of December 31, 2025.

• Market cap of $128 million and 27.3 million shares outstanding as of March 31, 2026.

• Stock added to the Russell 2000 and 3000 indexes in June 2025.

Leadership and commercial organization

• Senior management team has decades of experience in dermatology and pharmaceutical commercialization.

• Leadership previously launched brands generating over $2 billion in sales and played key roles at Medicis, which was sold for $2.5 billion.

• Sales force averages 9 years of dermatology experience, with 280 years combined, and covers 80% of the top 50 U.S. MSAs.

• Sales reps incentivized through equity rewards and entrepreneurial programs.

Product portfolio and growth drivers

• Five core dermatology brands, with Emrosi™ as the key growth driver.

• Emrosi™ launched in April 2025 for rosacea, showing head-to-head superiority over Oracea® in Phase 3 trials.

• Other brands include Qbrexza (hyperhidrosis), Amzeeq (acne), Accutane (severe acne), and Fzilxi (rosacea).

• Emrosi™ received FDA approval in November 2024 and is positioned to become the standard of care for rosacea.